Novo Nordisk A/S (NVO) Competitors

$46.02 +0.22 (+0.48%)

Closing price 05/8/2026 03:59 PM Eastern

Extended Trading

$45.87 -0.15 (-0.33%)

As of 05/8/2026 08:00 PM Eastern

NVO vs. AZN, NVS, SNY, GSK, and TAK

Should you be buying Novo Nordisk A/S stock or one of its competitors? The main competitors of Novo Nordisk A/S include Astrazeneca (AZN), Novartis (NVS), Sanofi (SNY), GSK (GSK), and Takeda Pharmaceutical (TAK). These companies are all part of the "pharmaceutical products" industry.

How does Novo Nordisk A/S compare to Astrazeneca?

Novo Nordisk A/S (NYSE:NVO) and Astrazeneca (NYSE:AZN) are both large-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

In the previous week, Novo Nordisk A/S had 46 more articles in the media than Astrazeneca. MarketBeat recorded 68 mentions for Novo Nordisk A/S and 22 mentions for Astrazeneca. Astrazeneca's average media sentiment score of 1.03 beat Novo Nordisk A/S's score of 0.56 indicating that Astrazeneca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	25 Very Positive mention(s)	13 Positive mention(s)	15 Neutral mention(s)	6 Negative mention(s)	5 Very Negative mention(s)	Positive
Astrazeneca	16 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Novo Nordisk A/S has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Astrazeneca has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500.

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Novo Nordisk A/S presently has a consensus target price of $65.56, suggesting a potential upside of 42.47%. Astrazeneca has a consensus target price of $205.33, suggesting a potential upside of 12.38%. Given Novo Nordisk A/S's higher possible upside, equities research analysts plainly believe Novo Nordisk A/S is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	18 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Novo Nordisk A/S has higher earnings, but lower revenue than Astrazeneca. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.39	$15.51B	$4.26	10.80
Astrazeneca	$58.74B	4.82	$10.23B	$6.66	27.43

Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.8%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.4%. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Novo Nordisk A/S has a net margin of 37.23% compared to Astrazeneca's net margin of 17.19%. Novo Nordisk A/S's return on equity of 63.31% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	37.23%	63.31%	22.19%
Astrazeneca	17.19%	30.86%	12.68%

Summary

Novo Nordisk A/S beats Astrazeneca on 10 of the 18 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Novartis?

Novo Nordisk A/S (NYSE:NVO) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

Novo Nordisk A/S has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.

Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.8%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.1%. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Novartis pays out 44.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Novo Nordisk A/S had 47 more articles in the media than Novartis. MarketBeat recorded 68 mentions for Novo Nordisk A/S and 21 mentions for Novartis. Novartis' average media sentiment score of 1.15 beat Novo Nordisk A/S's score of 0.56 indicating that Novartis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	25 Very Positive mention(s)	13 Positive mention(s)	15 Neutral mention(s)	6 Negative mention(s)	5 Very Negative mention(s)	Positive
Novartis	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Novo Nordisk A/S has higher earnings, but lower revenue than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.39	$15.51B	$4.26	10.80
Novartis	$54.53B	5.11	$13.98B	$6.98	20.91

Novo Nordisk A/S presently has a consensus target price of $65.56, suggesting a potential upside of 42.47%. Novartis has a consensus target price of $141.20, suggesting a potential downside of 3.28%. Given Novo Nordisk A/S's higher possible upside, equities research analysts plainly believe Novo Nordisk A/S is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	18 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by insiders. Comparatively, 0.0% of Novartis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Novo Nordisk A/S has a net margin of 37.23% compared to Novartis' net margin of 24.87%. Novo Nordisk A/S's return on equity of 63.31% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	37.23%	63.31%	22.19%
Novartis	24.87%	38.82%	15.16%

Summary

Novo Nordisk A/S beats Novartis on 10 of the 18 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Sanofi?

Novo Nordisk A/S (NYSE:NVO) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

Novo Nordisk A/S has a net margin of 37.23% compared to Sanofi's net margin of 16.95%. Novo Nordisk A/S's return on equity of 63.31% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	37.23%	63.31%	22.19%
Sanofi	16.95%	13.39%	7.58%

Novo Nordisk A/S currently has a consensus target price of $65.56, indicating a potential upside of 42.47%. Sanofi has a consensus target price of $51.00, indicating a potential upside of 17.76%. Given Novo Nordisk A/S's higher probable upside, analysts plainly believe Novo Nordisk A/S is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	18 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13
Sanofi	1 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.40

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by company insiders. Comparatively, 1.0% of Sanofi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Novo Nordisk A/S has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500.

In the previous week, Novo Nordisk A/S had 59 more articles in the media than Sanofi. MarketBeat recorded 68 mentions for Novo Nordisk A/S and 9 mentions for Sanofi. Sanofi's average media sentiment score of 0.77 beat Novo Nordisk A/S's score of 0.56 indicating that Sanofi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	25 Very Positive mention(s)	13 Positive mention(s)	15 Neutral mention(s)	6 Negative mention(s)	5 Very Negative mention(s)	Positive
Sanofi	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Novo Nordisk A/S has higher earnings, but lower revenue than Sanofi. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.39	$15.51B	$4.26	10.80
Sanofi	$47.35B	2.23	$8.84B	$3.58	12.10

Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.8%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.1%. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Sanofi pays out 49.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Novo Nordisk A/S beats Sanofi on 11 of the 19 factors compared between the two stocks.

How does Novo Nordisk A/S compare to GSK?

GSK (NYSE:GSK) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

15.7% of GSK shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 10.0% of GSK shares are held by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

GSK currently has a consensus target price of $53.00, indicating a potential upside of 5.20%. Novo Nordisk A/S has a consensus target price of $65.56, indicating a potential upside of 42.47%. Given Novo Nordisk A/S's stronger consensus rating and higher probable upside, analysts plainly believe Novo Nordisk A/S is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	3 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.90
Novo Nordisk A/S	1 Sell rating(s)	18 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13

Novo Nordisk A/S has a net margin of 37.23% compared to GSK's net margin of 17.82%. Novo Nordisk A/S's return on equity of 63.31% beat GSK's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
Novo Nordisk A/S	37.23%	63.31%	22.19%

Novo Nordisk A/S has higher revenue and earnings than GSK. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.37	$7.54B	$3.85	13.09
Novo Nordisk A/S	$46.80B	4.39	$15.51B	$4.26	10.80

GSK pays an annual dividend of $1.88 per share and has a dividend yield of 3.7%. Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.8%. GSK pays out 48.8% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Novo Nordisk A/S had 64 more articles in the media than GSK. MarketBeat recorded 68 mentions for Novo Nordisk A/S and 4 mentions for GSK. GSK's average media sentiment score of 1.19 beat Novo Nordisk A/S's score of 0.56 indicating that GSK is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novo Nordisk A/S	25 Very Positive mention(s)	13 Positive mention(s)	15 Neutral mention(s)	6 Negative mention(s)	5 Very Negative mention(s)	Positive

GSK has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.

Summary

Novo Nordisk A/S beats GSK on 14 of the 18 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Takeda Pharmaceutical?

Novo Nordisk A/S (NYSE:NVO) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Novo Nordisk A/S currently has a consensus target price of $65.56, suggesting a potential upside of 42.47%. Given Novo Nordisk A/S's higher probable upside, equities analysts clearly believe Novo Nordisk A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	18 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Novo Nordisk A/S has a net margin of 37.23% compared to Takeda Pharmaceutical's net margin of 2.58%. Novo Nordisk A/S's return on equity of 63.31% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	37.23%	63.31%	22.19%
Takeda Pharmaceutical	2.58%	10.60%	5.21%

Novo Nordisk A/S has higher revenue and earnings than Takeda Pharmaceutical. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.39	$15.51B	$4.26	10.80
Takeda Pharmaceutical	$30.09B	1.74	$712.33M	$0.24	68.69

Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.8%. Takeda Pharmaceutical pays an annual dividend of $0.50 per share and has a dividend yield of 3.0%. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 208.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Novo Nordisk A/S had 62 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 68 mentions for Novo Nordisk A/S and 6 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.74 beat Novo Nordisk A/S's score of 0.56 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	25 Very Positive mention(s)	13 Positive mention(s)	15 Neutral mention(s)	6 Negative mention(s)	5 Very Negative mention(s)	Positive
Takeda Pharmaceutical	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novo Nordisk A/S has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500.

Summary

Novo Nordisk A/S beats Takeda Pharmaceutical on 15 of the 18 factors compared between the two stocks.

Get Novo Nordisk A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVO vs. The Competition

Export

Metric	Novo Nordisk A/S	Large Cap Pharma Industry	Medical Sector	NYSE Exchange
Market Cap	$204.50B	$290.40B	$6.26B	$22.98B
Dividend Yield	3.82%	2.81%	2.78%	4.01%
P/E Ratio	10.80	25.69	20.74	28.60
Price / Sales	4.39	4.79	534.44	110.85
Price / Cash	9.77	12.43	43.29	25.08
Price / Book	6.46	6.75	9.96	4.62
Net Income	$15.51B	$11.61B	$3.55B	$1.07B
7 Day Performance	4.96%	-1.39%	3.48%	0.47%
1 Month Performance	22.99%	-2.95%	4.14%	4.11%
1 Year Performance	-30.01%	22.77%	41.80%	28.53%

Novo Nordisk A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVO Novo Nordisk A/S	4.8302 of 5 stars	$46.02 +0.5%	$65.56 +42.5%	N/A	$204.50B	$46.80B	10.80	69,505	Trending News Earnings Report Analyst Revision
AZN Astrazeneca	4.018 of 5 stars	$182.43 -2.3%	$102.67 -43.7%	N/A	$283.64B	$58.74B	31.50	96,100	Positive News Analyst Revision
NVS Novartis	3.5991 of 5 stars	$142.64 -2.0%	$141.20 -1.0%	N/A	$272.42B	$56.67B	19.94	75,267	Trending News Analyst Revision
SNY Sanofi	4.1637 of 5 stars	$45.44 -1.1%	$54.00 +18.8%	N/A	$110.98B	$49.35B	12.71	74,846	Analyst Revision
GSK GSK	3.6648 of 5 stars	$50.54 -7.2%	$53.00 +4.9%	N/A	$102.72B	$32.67B	13.68	66,841	Positive News Dividend Cut

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NVO) was last updated on 5/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novo Nordisk A/S (NVO) Competitors

NVO vs. AZN, NVS, SNY, GSK, and TAK

How does Novo Nordisk A/S compare to Astrazeneca?

Summary

How does Novo Nordisk A/S compare to Novartis?

Summary

How does Novo Nordisk A/S compare to Sanofi?

Summary

How does Novo Nordisk A/S compare to GSK?

Summary

How does Novo Nordisk A/S compare to Takeda Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVO vs. The Competition

Novo Nordisk A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novo Nordisk A/S (NVO) Competitors

NVO vs. AZN, NVS, SNY, GSK, and TAK

How does Novo Nordisk A/S compare to Astrazeneca?

Does the media favor NVO or AZN?

Which has more volatility and risk, NVO or AZN?

Do insiders and institutionals have more ownership in NVO or AZN?

Do analysts recommend NVO or AZN?

Which has higher earnings and valuation, NVO or AZN?

Is NVO or AZN a better dividend stock?

Is NVO or AZN more profitable?

Summary

How does Novo Nordisk A/S compare to Novartis?

Which has more volatility and risk, NVO or NVS?

Is NVO or NVS a better dividend stock?

Does the media favor NVO or NVS?

Which has higher earnings and valuation, NVO or NVS?

Do analysts recommend NVO or NVS?

Do insiders and institutionals have more ownership in NVO or NVS?

Is NVO or NVS more profitable?

Summary

How does Novo Nordisk A/S compare to Sanofi?

Is NVO or SNY more profitable?

Do analysts prefer NVO or SNY?

Do insiders & institutionals have more ownership in NVO or SNY?

Which has more volatility & risk, NVO or SNY?

Does the media refer more to NVO or SNY?

Which has stronger earnings & valuation, NVO or SNY?

Is NVO or SNY a better dividend stock?

Summary

How does Novo Nordisk A/S compare to GSK?

Do insiders and institutionals hold more shares of GSK or NVO?

Do analysts prefer GSK or NVO?

Is GSK or NVO more profitable?

Which has higher earnings and valuation, GSK or NVO?

Is GSK or NVO a better dividend stock?

Does the media prefer GSK or NVO?

Which has more risk and volatility, GSK or NVO?

Summary

How does Novo Nordisk A/S compare to Takeda Pharmaceutical?

Do insiders & institutionals have more ownership in NVO or TAK?

Do analysts prefer NVO or TAK?

Is NVO or TAK more profitable?

Which has higher earnings and valuation, NVO or TAK?

Is NVO or TAK a better dividend stock?

Does the media favor NVO or TAK?

Which has more volatility and risk, NVO or TAK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVO vs. The Competition

Novo Nordisk A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools